Blinded by rare disorder, Alberta man fundraising to regain vision

Related Posts

16 Feb

Once legally blind, now 20/20

This past month has been nothing short of miraculous in the personal and professional life of K.C. Ryder, a…

read more
16 Aug

Corbus to Start Phase 3 Anabasum Trial in Scleroderma Patients by Year’s End

Corbus Pharmaceuticals says a Phase 3 clinical trial of anabasum for diffuse cutaneous scleroderma will start in the fourth…

read more
20 Jun

eSight and Varioptic announce the availability of eSight 3 electronic glasses

Varioptic is happy to announce that its advanced Caspian module is a part of the recently launched eSight 3,…

read more
07 Mar

First Patient Dosed in Neuraly’s NLY01 Trial Testing Safety, Efficacy

The first patient has been dosed in a Phase 2 study testing NLY01, an investigational compound with a new…

read more
08 Jun

Ultracell Insulation $850000 Fundraising. Jonathan Strimling Filed Jun 7 Form D

Ultracell Insulation, Llc, Limited Liability Company just submitted form D about $850,000 debt financing. This is a new filing….

read more
02 Mar

Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced…

read more
29 Oct

Andrews McMeel Universal Partners with ImageRights to Tackle Copyright Infringement

ImageRights International, the world’s leading copyright enforcement service, today announces Andrews McMeel Universal (AMU) will be using its image…

read more
08 Jul

Employers Boost Use Of Digital Tools To Stamp Out Student Debt

The student debt crisis is something of a ticking time bomb, and employers are increasingly stepping up by offering…

read more
07 Dec

How This Prenatal Vitamin Startup has Achieved Fast-Paced Growth

Dan Aziz stood outside of pharmacies surveying pregnant women for market research before starting his company, Luna Pharmaceuticals, which…

read more
05 Apr

Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies, Antibody-Drug Conjugates, and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of two posters featuring new…

read more